地黄骨痛康胶囊治疗肝肾亏虚型膝骨关节炎的临床研究
|
摘要
目的:观察地黄骨痛康胶囊治疗肝肾亏虚型膝骨关节炎的临床疗效及安全性。方法:采用随机分组原则,将120例膝骨关节炎患者分为治疗组和对照组(各60例),治疗组口服地黄骨痛康胶囊,对照组口服尪痹胶囊,比较两组患者临床疗效。结果:治疗组总有效率高于对照组,差异有统计学意义(P<0.05)。结论:地黄骨痛康胶囊组方独特、疗效可靠,随访未发现明显不良反应,不仅明显缓解了局部疼痛症状,还能显著改善膝关节的活动功能,值得在临床推广应用。
Objective:To observe the clinical efficacy and safety of Dihuang Gutongkang capsule in the treatment of knee osteoarthritis due to Liver-kidney Deficiency type.Methods:According to the principle of random grouping,120 patients with knee osteoarthritis were divided into treatment group and control group,60 cases in each group.The treatment group took Dihuang Gutongkang capsule orally,while the control group took Wangbi capsule orally.The clinical efficacy of the two groups was compared.Results:The total effective rate of the treatment group was higher than that of the control group(P<0.05).Conclusion:Dihuang Gutongkang capsule has unique prescription and reliable curative effect.No obvious adverse reactions were found during follow-up.It not only alleviates local pain symptoms,but also significantly improves knee joint function.The curative effect is better than that of the control group.It is worth popularizing and applying in clinic.
Objective:To observe the clinical efficacy and safety of Dihuang Gutongkang capsule in the treatment of knee osteoarthritis due to Liver-kidney Deficiency type.Methods:According to the principle of random grouping,120 patients with knee osteoarthritis were divided into treatment group and control group,60 cases in each group.The treatment group took Dihuang Gutongkang capsule orally,while the control group took Wangbi capsule orally.The clinical efficacy of the two groups was compared.Results:The total effective rate of the treatment group was higher than that of the control group(P<0.05).Conclusion:Dihuang Gutongkang capsule has unique prescription and reliable curative effect.No obvious adverse reactions were found during follow-up.It not only alleviates local pain symptoms,but also significantly improves knee joint function.The curative effect is better than that of the control group.It is worth popularizing and applying in clinic.
引文
[1] 昊林生,金嫣莉.膝痛[M].北京:人民卫生出版社,2010:347.
[2] ANDRIACCHI T P,FAVRE J,ERHART-HLEDIK J C,et al.A systems view of risk factors for knee osteoarthritis reveals insights into the pathogenesis of the disease[J].Annals of Biomedical Engineering,2015,43(2):376-387.
[3] TANG X,WANG S,ZHAN S,et al.The prevalence of symptomatic knee osteoarthritis in China results from the China health and retirement longitudinal study[J].Arhrritis Rheumatol,2016,68(3):648-653.
[4] 王斌,邢丹,林剑浩.骨关节炎诊治指南的临床转化应用[J].中华关节外科杂志:电子版,2017,11(1):104-108.
[5] 国家食品药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:115-119.
[6] ALTMAN R,ASCH E,BLOCH D,et al.Development of criteris for the classification and reporting of osteoarthritis,classification of knee[J].Arthritis Rheum,1986,29(8):1039-1049.
[7] 阎小萍.常见风湿病及相关骨科疾病中西医结合诊治[M].北京:人民卫生出版社,2015:39.
[8] MATZKIN E G,CURRY E J,KONG Q,et al.Efficacy and treatment response of intra-articular corticosteroid injections in patients with symptomatic knee osteoarthritis[J].J Am Acad Orthop Surg,2017,25(10):703-714.
[9] 陈文锦,华臻,周智毅,等.关节腔内注射氧-臭氧治疗膝骨关节炎的临床疗效[J].江苏医药,2019,45(1):31-34.
[10] KO W,SOHN J H,JANG J H,et al.Inhibitory effects of alternaramide on inflammatory mediator expression through TLR4 MyD88 mediated inhibition of NF-кB and MAPK pathway signaling in lipopolysaccharide stimulated RAW264.7 and BV2 cells[J].Chem Biol Interact,2016,244:16.
[11] 苏晓恩,孔志强,朱娟,等.膝关节骨关节炎软骨中YKL-40、IL-1β的表达及相关性探讨[J].重庆医学,2017,46(4):480-482.
[12] 殷松江,邢润麟,王培民.基于TRP离子通道谈“以痛为枢、截断扭转”理论诊治膝骨关节炎的分子机制[J].中华中医药学刊,2018,36(11):2655-2658.
[13] 刘恒平,方心,薛斌,等.尪痹制剂与非甾体抗炎药对比治疗膝骨关节炎的随机对照试验的系统评价[J].河北中医,2017,39(2):180-184.
[14] 田镭,钟琴,马武开,等.独活寄生汤治疗膝骨关节炎的研究进展[J].风湿病与关节炎,2019,8(1):66-68.
[15] 申海艳,周静.中医外治法治疗膝骨关节炎的研究进展[J].风湿病与关节炎,2018,7(12):64-67.
[16] 赵颖林,张满成,李延红,等.活络止痛软膏治疗膝骨关节炎49例[J].中国中医骨伤科杂志,2013,21(10):43-44.
[17] 李延红,张宏蕾,石耀武,等.活络止痛软膏治疗膝骨关节炎60例[J].中国中医骨伤科杂志,2014,22(10):36-37.
[2] ANDRIACCHI T P,FAVRE J,ERHART-HLEDIK J C,et al.A systems view of risk factors for knee osteoarthritis reveals insights into the pathogenesis of the disease[J].Annals of Biomedical Engineering,2015,43(2):376-387.
[3] TANG X,WANG S,ZHAN S,et al.The prevalence of symptomatic knee osteoarthritis in China results from the China health and retirement longitudinal study[J].Arhrritis Rheumatol,2016,68(3):648-653.
[4] 王斌,邢丹,林剑浩.骨关节炎诊治指南的临床转化应用[J].中华关节外科杂志:电子版,2017,11(1):104-108.
[5] 国家食品药品监督管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:115-119.
[6] ALTMAN R,ASCH E,BLOCH D,et al.Development of criteris for the classification and reporting of osteoarthritis,classification of knee[J].Arthritis Rheum,1986,29(8):1039-1049.
[7] 阎小萍.常见风湿病及相关骨科疾病中西医结合诊治[M].北京:人民卫生出版社,2015:39.
[8] MATZKIN E G,CURRY E J,KONG Q,et al.Efficacy and treatment response of intra-articular corticosteroid injections in patients with symptomatic knee osteoarthritis[J].J Am Acad Orthop Surg,2017,25(10):703-714.
[9] 陈文锦,华臻,周智毅,等.关节腔内注射氧-臭氧治疗膝骨关节炎的临床疗效[J].江苏医药,2019,45(1):31-34.
[10] KO W,SOHN J H,JANG J H,et al.Inhibitory effects of alternaramide on inflammatory mediator expression through TLR4 MyD88 mediated inhibition of NF-кB and MAPK pathway signaling in lipopolysaccharide stimulated RAW264.7 and BV2 cells[J].Chem Biol Interact,2016,244:16.
[11] 苏晓恩,孔志强,朱娟,等.膝关节骨关节炎软骨中YKL-40、IL-1β的表达及相关性探讨[J].重庆医学,2017,46(4):480-482.
[12] 殷松江,邢润麟,王培民.基于TRP离子通道谈“以痛为枢、截断扭转”理论诊治膝骨关节炎的分子机制[J].中华中医药学刊,2018,36(11):2655-2658.
[13] 刘恒平,方心,薛斌,等.尪痹制剂与非甾体抗炎药对比治疗膝骨关节炎的随机对照试验的系统评价[J].河北中医,2017,39(2):180-184.
[14] 田镭,钟琴,马武开,等.独活寄生汤治疗膝骨关节炎的研究进展[J].风湿病与关节炎,2019,8(1):66-68.
[15] 申海艳,周静.中医外治法治疗膝骨关节炎的研究进展[J].风湿病与关节炎,2018,7(12):64-67.
[16] 赵颖林,张满成,李延红,等.活络止痛软膏治疗膝骨关节炎49例[J].中国中医骨伤科杂志,2013,21(10):43-44.
[17] 李延红,张宏蕾,石耀武,等.活络止痛软膏治疗膝骨关节炎60例[J].中国中医骨伤科杂志,2014,22(10):36-37.